Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 3/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | GRK5 | P34947 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2544857 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CCR2DRD4UBE2MDCUN1D1 | |
| SCHEMBL2543843 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CCR2DRD4UBE2MDCUN1D1 | |
| SCHEMBL2364115 | 0.92 | SIGMAR1 (0.65) | SIGMAR1CCR2CHRM4DRD4CHRM3 | |
| SCHEMBL2309233 | 0.87 | SIGMAR1 (0.67) | SIGMAR1CCR2CHRM4DRD4CHRM3 | |
| SCHEMBL2545118 | 0.87 | SIGMAR1 (0.41) | SIGMAR1FAAHDRD4 | |
| SCHEMBL2308735 | 0.82 | FAAH (0.53) | SIGMAR1FAAHCHRM4OPRL1CHRM3 | |
| SCHEMBL2544859 | 0.82 | SIGMAR1 (0.43) | SIGMAR1 | |
| SCHEMBL2536834 | 0.82 | CACNA1B (0.56) | SIGMAR1FAAHCCR2CHRM4OPRL1 | |
| SCHEMBL2538478 | 0.82 | CACNA1B (0.56) | SIGMAR1FAAHCCR2CHRM4OPRL1 | |
| SCHEMBL2536831 | 0.82 | CACNA1B (0.56) | SIGMAR1FAAHCCR2CHRM4OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | claimed |
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | SIGMAR1 676/4885FAAH 2437/4885CCR2 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.